Ingenza opens inGenius Building with Princess Royal visit

The Edinburgh-based protein engineering CRDMO has more than doubled its operational footprint with a new multimillion-pound facility at Edinburgh Technopole.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A row of large, gleaming stainless steel bioreactors with extensive piping and integrated control panels lines a brightly lit, sterile cleanroom facility.

Ingenza, the Edinburgh-based contract research, development and manufacturing organisation specialising in protein engineering, has officially opened its new inGenius Building at Pioneer Group's Edinburgh Technopole site. The ceremony was marked by a visit from Her Royal Highness The Princess Royal, who toured the facility and met with senior staff and long-term commercial partners.

Chief executive Nick Challoner said the new building had "more than doubled" Ingenza's operational footprint and would allow the company to scale across headcount, technology and customer reach. The facility sits within Edinburgh Technopole, an established life sciences and animal health research cluster on the outskirts of the Scottish capital.

Expanding capacity at a critical growth stage

The inGenius Building is designed to accommodate the growth demands of Ingenza's CRDMO model, which serves customers across pharmaceuticals, industrial biotechnology and sustainable technology. The company's platform, also branded inGenius, draws on twelve alternative host systems alongside proprietary tools for gene design and high-throughput screening to accelerate bioprocess development from early-stage targets through to commercialisation.

Among the guests at the opening was Michael Giambalvo, president of Phibro Animal Health Corporation, who described the Ingenza partnership as spanning more than a decade. The relationship illustrates the kind of long-term, repeat-customer dynamic that CRDMOs depend on for stable revenue, and its visibility at a high-profile ceremonial event signals Ingenza's confidence in the commercial relationship.

Market context and competitive landscape

The CRDMO space for protein engineering and bioprocess development has grown considerably over the past five years, driven by demand from biologics manufacturers seeking external capacity and specialist expertise rather than building in-house. Scotland has cultivated a credible cluster of engineering biology companies, with Ingenza positioned as one of the more established players given its 24-year operating history.

Ingenza has also been developing its UNVAIL platform, described in accompanying materials as an AI and machine-learning-powered tool for discovering novel proteins with improved properties for industrial applications.

Sector

Topic

Geography